Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
Xenon Pharmaceuticals Inc (NASDAQ: XENE) closed the day trading at $41.0 down -1.89% from the previous closing price of $41.79. In other words, the price has decreased by -$1.89 from its previous closing price. On the day, 1.48 million shares were traded. XENE stock price reached its highest trading level at $42.27 during the session, while it also had its lowest trading level at $40.41.
Ratios:
For a better understanding of XENE, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.52 and its Current Ratio is at 12.52. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On May 07, 2025, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $55.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $67.Deutsche Bank initiated its Buy rating on February 11, 2025, with a $67 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 02 ’26 when MORTIMER IAN sold 40,000 shares for $44.43 per share. The transaction valued at 1,777,093 led to the insider holds 6,000 shares of the business.
IAN MORTIMER bought 40,000 shares of XENE for $1,777,166 on Jan 02 ’26. On Dec 05 ’25, another insider, MORTIMER IAN, who serves as the PRESIDENT & CEO of the company, sold 14,375 shares for $45.03 each. As a result, the insider received 647,306 and left with 16,830 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XENE now has a Market Capitalization of 3168275456 and an Enterprise Value of 2714334208. For the stock, the TTM Price-to-Sale (P/S) ratio is 422.44 while its Price-to-Book (P/B) ratio in mrq is 5.65. Its current Enterprise Value per Revenue stands at 361.911 whereas that against EBITDA is -8.026.
Stock Price History:
The Beta on a monthly basis for XENE is 0.97, which has changed by 0.056637168 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, XENE has reached a high of $46.60, while it has fallen to a 52-week low of $26.74. The 50-Day Moving Average of the stock is -3.41%, while the 200-Day Moving Average is calculated to be 11.79%.
Shares Statistics:
Over the past 3-months, XENE traded about 807.57K shares per day on average, while over the past 10 days, XENE traded about 836760 shares per day. A total of 77.12M shares are outstanding, with a floating share count of 74.76M. Insiders hold about 3.26% of the company’s shares, while institutions hold 106.69% stake in the company. Shares short for XENE as of 1765756800 were 5720672 with a Short Ratio of 7.08, compared to 1763078400 on 6043619. Therefore, it implies a Short% of Shares Outstanding of 5720672 and a Short% of Float of 8.25.
Earnings Estimates
Current recommendations for the stock of the company come from 13.0 analysts. The consensus estimate for the next quarter is -$1.13, with high estimates of -$0.95 and low estimates of -$1.23.
Analysts are recommending an EPS of between -$4.12 and -$4.55 for the fiscal current year, implying an average EPS of -$4.27. EPS for the following year is -$4.57, with 15.0 analysts recommending between -$2.15 and -$5.33.
